US EditionBispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management - ILCN.org (ILCN/WCLC)
Dr. Melissa L. Johnson, director of lung cancer research at Sarah Cannon Research Institute, took the podium in an education session on bispecific T-cell engagers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting this past June. Dr. Johnson discussed some of the obstacles that community practices face in implementing these novel agents, especially regarding the potentially serious associated side effects of cytokine release…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
